Paul Marks (scientist)
Paul Marks | |
|---|---|
| Born | August 16, 1926 |
| Alma mater | |
| Known for | Paul Marks Prize for Cancer Research |
| Scientific career | |
| Institutions | |
Paul A. Marks is a medical doctor, researcher and administrator. He is a faculty member and president emeritus at Memorial Sloan Kettering Cancer Center.[1][2]
Contents
Background[edit]
Marks was born in Brooklyn, New York, in 1926. Marks attended Columbia College and Columbia Medical School. After completing postdoctoral research at the United States National Institutes of Health and at the Institut Pasteur in France, he joined the faculty at Columbia University. Marks served as dean of the Medical Faculty at Columbia University from 1970 to 1973.[3] He was president and chief executive officer at Memorial Sloan Kettering from 1980 until 1999.[3]
Scholarly activities[edit]
Marks has contributed to the fields of genetics and oncology.[3] His recent work has focused on histone deacetylases (HDACs) and chemicals that interfere with HDAC enzymatic activities (HDAC inhibitors or HDIs). Marks and others have found that drugs such as Trichostatin A and SAHA (vorinostat) can serve as anticancer agents.[4]
Marks has published more than 400 scientific articles and has been the editor-in-chief of journals including the Journal of Clinical Investigation and Blood.[5]
Honors and affiliations[edit]
- Member, National Academy of Sciences[3]
- Member, Institute of Medicine[3]
- Recipient, President's National Medal of Science[5]
- Fellow, American Academy of Arts and Sciences[3]
- Fellow, The American Philosophical Society[5]
Paul Marks Prize for Cancer Research[edit]
The Paul Marks Prize for Cancer Research was established by Memorial Sloan Kettering to honor Marks's contributions "as a distinguished scientist and leader".[3] The prize has been awarded every two years since 2001.
References[edit]
- ^ Memorial Sloan Kettering Cancer Center biography
- ^ Businessweek profile
- ^ a b c d e f g MSKCC Paul Marks Prize website
- ^ Marks, P. A.; Breslow, R. (2007). "Dimethyl sulfoxide to vorinostat: Development of this histone deacetylase inhibitor as an anticancer drug". Nature Biotechnology. 25 (1): 84–90. doi:10.1038/nbt1272. PMID 17211407.
- ^ a b c PTC Therapeutics Archived 2014-10-02 at the Wayback Machine
Authority control  |
|
|---|
